Hydroxyurea treatment of children with hemoglobin SC disease
Pediatric Blood & Cancer2012Vol. 60(2), pp. 323–325
Citations Over Time
Amber M. Yates, Laurence Dedeken, Matthew P. Smeltzer, Jeffrey D. Lebensburger, Winfred C. Wang, Nancy Robitaille
Abstract
The efficacy of hydroxyurea in hemoglobin SC (HbSC) patients is not well documented. We describe the long-term response to hydroxyurea in children with clinically severe HbSC. In 15 patients, hydroxyurea resulted in a significant increase in mean corpuscular volume (MCV) and fetal hemoglobin (HbF) and a significant decrease in episodes of acute chest syndrome and hospitalization for pain; there was no effect on hemoglobin level. The most significant side effect was thrombocytopenia, which led to discontinuation of treatment in one patient. This study suggests that hydroxyurea has efficacy and is safe for long-term therapy in patients with HbSC.
Related Papers
- → A clinically meaningful fetal hemoglobin threshold for children with sickle cell anemia during hydroxyurea therapy(2017)82 cited
- → Early initiation of hydroxyurea (hydroxycarbamide) using individualised, pharmacokinetics‐guided dosing can produce sustained and nearly pancellular expression of fetal haemoglobin in children with sickle cell anaemia(2021)37 cited
- → HEMATOLOGIA DE JUNDIÁS EM RESPOSTA AO NÍVEL DE PROTEÍNA NA DIETA(2011)4 cited
- → Association of BMI (Body Mass Index) to hemoglobin and red blood cell indices among adolescents.(2020)3 cited
- Research Article Effect of Aluminium Chloride and Protective Effect of Ginger Extract on Hematological Profiles in Male Wistar Rats(2015)